Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted ...

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology™ platform EVX-04 is a therapeutic cancer vaccine candidate ...

75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-up Immune activation ...

New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting Following the recent presentation of unprecedented two-year clinical efficacy data from ...

The human papillomavirus (HPV) vaccine is one of the few vaccines proven to prevent cancer-so why have only 61% of teens 13-17 and far lower percentages of younger children received the potentially ...

Nil Adell-Mill is pioneering a new era of chemistry by teaching machines to innovate through biology-inspired models, transforming research, discovery, and materials science.

The U.S. government has canceled $500 million in funding for mRNA vaccine research, raising concerns about future vaccine development. Kristen Dahlgren, CEO of the Cancer Vaccine Coalition, remains ...

Cervical cancer remains one of the most preventable yet deadly cancers for women worldwide, with vast disparities between high-income nations and low- and middle-income countries. Recent research ...